Certara, Inc. (CERT) Aug 2024 Earnings Report
Certara, Inc.: Investment Report
Overview
Certara, Inc. is a leading provider of software products and technology-enabled services for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. With a strong presence in the healthcare sector, Certara has established itself as a key player in the health information services industry. This report provides an in-depth analysis of Certara's financial performance, growth prospects, and recent news, making it an essential read for investors seeking to understand the company's potential.
Core Metrics
- Current price: 13.03 USD
- 52-week high: 19.87 USD
- 52-week low: 11.81 USD
- Market Cap: 2.096 billion USD
- P/E Ratio: N/A (due to negative EPS)
- Earnings per Share: -0.5 USD
- 50-day average: 15.2144 USD
- 200-day average: 16.108774 USD
- Analyst Recommendations: Buy (9 analysts)
Financial Performance
Certara's latest quarterly earnings report showed a miss on expectations, with reported EPS of -$0.07834 compared to expectations of $0.11. The company's revenue growth rate is 3.2%, and its gross margins and EBITDA margins are 59.01% and 19.45%, respectively. Certara's free cash flow is 86.32 million USD, and its operating cash flow is 68.85 million USD. The company's EBITDA is 70.72 million USD.
Growth Prospects
Certara's growth prospects are promising, driven by the increasing demand for biosimulation in drug discovery and development. The company's solutions for model-informed drug development and biosimulation are expected to continue driving revenue growth. Additionally, Certara's expanding presence in the health information services industry is likely to provide further growth opportunities.
News and Updates
Recent news articles highlight Certara's Q2 2024 earnings call transcript, where the company discussed its financial performance and future outlook. Additionally, CERT-In, an agency under the Ministry of Electronics and Information Technology, has issued critical advisories concerning users of Microsoft Edge browser and Apple devices, including iPhone, VisionPro headset, Mac, iPad, and Apple Watch, due to multiple vulnerabilities in their software.
Upgrades and Downgrades
According to recent analyst recommendations, UBS and Baird have maintained their Neutral ratings for Certara, while Keybanc has reinitiated coverage with an Overweight rating. JMP Securities has maintained its Market Perform rating, and Barclays has maintained its Equal-Weight rating.
Summary
In conclusion, Certara, Inc. presents an attractive investment opportunity, driven by its strong position in the healthcare sector and growing demand for biosimulation solutions. While the company's latest earnings report was disappointing, its growth prospects and expanding presence in the health information services industry are promising. With a majority of analysts recommending a Buy, Certara is an attractive option for investors seeking exposure to the healthcare sector.
Disclosures
The information on this website should not be construed as or relied upon in any manner as investment, legal, tax, or other advice. You should consult your own advisers as to legal, business, tax, and other related matters concerning any investment. Any projections, estimates, forecasts, targets, prospects and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others. Any charts provided here or on other content distribution outlets are for informational purposes only, and should not be relied upon when making any investment decision. Under no circumstances should any information provided on this website or social media platforms be construed as an offer soliciting the purchase or sale of any security, nor should it be construed as an offer to provide investment advisory services.